Another significant milestone for cell therapy! This week, the FDA approved Adaptimmune’s T-cell immunotherapy to treat synovial sarcoma, a rare form of cancer that usually occurs in soft tissue. It is the first approval of an engineered cell therapy in the US to treat a solid tumor and the first new therapy option for synovial sarcoma approved in more than a decade. This milestone marks the second approval of a cell therapy to treat a solid tumor this year -- none were approved before 2024 – and is another example of an innovative sector bringing new hope to patients. https://lnkd.in/gp68yd6U #CellTherapy #Oncology
Alliance for Regenerative Medicine
Biotechnology Research
Washington, District of Columbia 24,256 followers
We champion the benefits of engineered cell therapies & genetic medicines for patients, healthcare systems & society.
About us
The Alliance for Regenerative Medicine (ARM) is the leading international advocacy organization championing the benefits of engineered cell therapies and genetic medicines for patients, healthcare systems, and society. As a community, ARM builds the future of medicine by convening the sector, facilitating influential exchanges on policies and practices, and advancing the narrative with data and analysis. We actively engage key stakeholders to enable the development of advanced therapies and modernize healthcare systems so that patients benefit from durable, potentially curative treatments. As the global voice of the sector, we represent more than 400 members across 25 countries, including emerging and established biotechnology companies, academic and medical research institutions, and patient organizations. To learn more about ARM or to become a member, visit http://www.alliancerm.org.
- Website
-
http://alliancerm.org
External link for Alliance for Regenerative Medicine
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Washington, District of Columbia
- Type
- Nonprofit
- Founded
- 2009
Locations
-
Primary
1015 18th St NW
Suite 1102
Washington, District of Columbia 20006, US
Employees at Alliance for Regenerative Medicine
Updates
-
How can cell therapy be enhanced for fighting cancer? Researchers at Penn Medicine have found evidence that suggests knocking out the CD5 protein with CRISPR-Cas9 could enhance the function of CAR-T cell therapies against multiple cancers. https://lnkd.in/gSQMTsKp #CellTherapy #Oncology
Knockout of CD5 on CAR T Cells Boosts Anti-Tumor Efficacy
pennmedicine.org
-
A story of hope and resilience. Cure Today shares the journey of Mindy, a patient who had multiple myeloma and is now in remission after receiving a CAR-T cell therapy. Read the full article here: https://lnkd.in/eRpbADWp #CellTherapy
My Decision to Receive CAR-T Cell Therapy for Multiple Myeloma
curetoday.com
-
Some cell and gene therapy treatments, including FDA-approved therapies to durably treat -- and potentially cure -- sickle cell disease, require chemotherapy and can therefore cause infertility. No patient should have to choose between receiving a transformative medicine and having biological children. In February, ARM wrote a letter to the Office of the Inspector General within the Department of Health and Human Services (HHS) urging them to allow cell and gene therapy companies to pay for fertility preservation services for affected patients in federal healthcare programs. We reiterate this call so that patients, including those from vulnerable populations, do not face barriers in accessing cell and gene therapies. View the letter here: https://lnkd.in/e9ctTmY7
-
Announcing ARM's Cell-Based Immuno-oncology Workshop! 🛠️ 🔬 Join us to assess the current and future state of adoptive cell therapy and autologous and allogeneic cellular immunotherapies. Hear from ARM member developers on regulatory, manufacturing, and commercialization challenges. The workshop will also highlight new developments in the field. 📅 September 5-6 📍 Philadelphia, PA & Virtual Learn more and register here: https://lnkd.in/egWwhjpt #CellTherapy #Oncology
-
What's new this week? More promising clinical news for the #cellandgenetherapy sector. ✅ European Commission approves gene therapy for severe hemophilia B – second approved in region 📋FDA accepts BLA for cell therapy to treat Steroid-Refractory Acute Graft-Versus Host Disease 🔬Data shows that gene therapy for hemophilia A achieved primary endpoint in late-stage trials Read the full stories below and subscribe to our Sector Vector newsletter for more weekly cell and gene therapy clinical, business, and manufacturing news. 📩 https://lnkd.in/e9H6syK6 This week, the European Commission announced that it had granted conditional marketing authorization for Pfizer's DURVEQTIX, a gene therapy for the treatment of severe and moderately severe hemophilia B. https://lnkd.in/ew-NiGSR The FDA has announced it accepted a BLA for Mesoblast Limited's cell therapy to treat children with Steroid-Refractory Acute Graft-Versus Host Disease. It has an assigned PDUFA date of January 7, 2025. https://lnkd.in/ePZvDc6n Pfizer announced topline results from its Phase 3 for an investigational gene therapy that Sangamo Therapeutics, Inc. is co-developing with Pfizer for the treatment of adults with moderately severe to severe hemophilia A.
-
Another gene therapy approval for the year! This week, the European Commission approved Pfizer's gene therapy for hemophilia B, which was endorsed by the EMA CHMP earlier this summer. This marks the EU's second gene therapy option for patients with severe hemophilia B. The therapy was approved in Canada in December 2023 and in the United States in April 2024. https://lnkd.in/ew-NiGSR
European Commission Approves Pfizer's DURVEQTIX® (fidanacogene elaparvovec), a One-Time Gene Therapy for Adults with Hemophilia B | Pfizer
pfizer.com
-
Will we soon see in-vivo CAR-T therapies? The first patient is set to receive this promising approach in an Australian clinical trial for B-cell malignancies. Researchers believe this new therapeutic approach can help provide more treatment options for patients, with some potentially being faster, safer, and cheaper. https://lnkd.in/gjEZ4DWM #CellTherapy #InVivo
A faster, simpler, cheaper cancer cell therapy is about to be tested in humans
https://www.statnews.com
-
An amazing breakthrough in cell therapy took place this month! By the time she reached 21, Janina’s liver and kidneys were failing due to complications from lupus. With few other options, her family turned to CAR-T cell therapy. Within days, most of her severe symptoms receded. Oliver Barnes covers her story and CAR-T cell therapy's promise for treating autoimmune diseases in the Financial Times. https://lnkd.in/gxs7ssg4 #CellTherapy #Lupus
Cell therapy offers ‘single shot’ hope to autoimmune disease patients
ft.com
-
We've just announced the 120+ leading companies and organizations presenting at ARM's 2024 Cell & Gene Meeting on the Mesa! 🧬🌵 View the initial slate 👉 https://lnkd.in/g2VBgWht Collectively, this slate covers several unique products with an extensive range of possible therapeutic applications. In addition to the presenters, hundreds of different organizations on the cutting edge of cell and gene therapy will also be in attendance. Don't miss your chance to meet with senior executives from the sector's leading companies - register for the conference today! https://lnkd.in/eiUpMy4 #CGMesa24